Table 3.
Analysis of prognostic scores versus CHR versus cytogenetic response
| Scoring system | Risk | Pediatric and adolescent patients | Adult patients | Pediatric and adolescent patients | Adult patients | ||||
|---|---|---|---|---|---|---|---|---|---|
| CHR | No CHR | CHR | No CHR | MCgR | mCgR | MCgR | mCgR | ||
| Sokal | Low | 17 (94.4%) | 01 (5.6%) | 05 (100%) | – | 15 (88.2%) | 02 (11.7%) | 05 (100%) | – |
| Intermediate | 17 (89.5%) | 02 (10.5%) | 21 (91.3%) | 02 (8.7%) | 17 (94.4%) | 01 (5.5%) | 22 (95.6%) | 01 (4.4%) | |
| High | 08 (88.9%) | 01 (11.1%) | 15 (93.8%) | 01 (6.3%) | 08 (88.8%) | 01 (11.1%) | 15 (93.7%) | 01 (6.3%) | |
| Hasford | Low | 14 (87.5%) | 02 (12.5%) | 14 (100%) | – | 13 (86.6%) | 02 (13.4%) | 13 (92.8%) | 01 (7.2%) |
| Intermediate | 23 (92%) | 02 (8%) | 19 (86.4%) | 03 (13.6%) | 22 (91.6%) | 02 (8.4%) | 21 (95.4%) | 01 (4.6%) | |
| High | 05 (100%) | – | 8 (100%) | – | 05 (100%) | – | 08 (100%) | – | |
| EUTOS | Low | 24 (92.3%) | 02 (7.7%) | 26 (96.3%) | 01 (3.7%) | 22 (88%) | 03 (12%) | 26 (96.2%) | 01 (3.8%) |
| High | 18 (90%) | 02 (10%) | 15 (88.2%) | 02 (11.8%) | 18 (94.7%) | 01 (5.3%) | 16 (94.1%) | 01 (5.9%) | |